Editorial pubs.acs.org/chemneuro
Cite This: ACS Chem. Neurosci. 2019, 10, 1116−1116
Call for Papers: Strategies and Tactics in CNS Drug Synthesis
ACS Chem. Neurosci. 2019.10:1116-1116. Downloaded from pubs.acs.org by 5.189.203.105 on 03/22/19. For personal use only.
I
Please let me know if this is of any interest to you as a potential author/coauthor. I think this new ongoing Review series will be highly read and cited, as well as serving as an invaluable teaching tool to graduate students. If interested in contributing, please e-mail me at either craig.lindsley@ vanderbilt.edu or
[email protected], and let me know which class of CNS drug synthesis you wish to review. Many thanks for your consideration of this Call for Papers, and I hope you are able to contribute.
n 2017, I put out a Call for Papers for a special issue on DARK Classics in Chemical Neuroscience, expanding our Classics review series from key CNS drugs and tool compounds to illicit drugs (DOI: 10.1021/acschemneuro.7b00306). The response for contributions was overwhelming, and the special DARK Classics issue, published in October of 2018, was one of our most highly read and downloaded to date (DOI: 10.1021/acschemneuro.8b00528). The demand was so high, that the DARK Classics are now an ongoing Review series in the Journal (more submissions desired). In addition to in-depth reviews on PCP, LSD, cocaine, fentanyl, DMT, psilocybin, mescaline, ibogaine, opium, and many others, Professor Stephen Townsend contributed an amazing review on the synthesis of illicit drugs entitled “The DARK Side of Total Synthesis: Strategies and Tactics in Psychoactive Drug Production” covering both pharmaceutical and clandestine chemistry approaches (DOI: 10.1021/acschemneuro.7b00528). This holistic review has been downloaded and read over 2300 times and sits among the top 5% of all research outputs scored by Altmetric.
■
AUTHOR INFORMATION
ORCID
Craig W. Lindsley: 0000-0003-0168-1445 Notes
Views expressed in this editorial are those of the author and not necessarily the views of the ACS.
Clearly, a Review of this type hit a nerve within the community and garnered great interest. Based on this, I am pleased to put out a Call for Papers to make this Review type another ongoing series within ACS Chemical Neuroscience, the Strategies and Tactics in CNS Drug Synthesis: WXYZ. For example, I could envision reviews such as (1) Strategies and Tactics in CNS Drug Synthesis: Typical Antipsychotics, (2) Strategies and Tactics in CNS Drug Synthesis: Antidepressants, (3) Strategies and Tactics in CNS Drug Synthesis: Dopamine Agonists, (4) Strategies and Tactics in CNS Drug Synthesis: Atypical Antipsychotics, (5) Strategies and Tactics in CNS Drug Synthesis: GlyT1 Inhibitors, and so on. These are just suggestionswith 100 years of CNS discovery across GPCRs, ion channels, and transporters, the potential content is unlimited. In each Review, medicinal chemistry and process chemistry routes could be compared and contrastedwhat a unique Review series this will be for the community. © 2019 American Chemical Society
Craig W. Lindsley, Editor-in-Chief
Published: March 20, 2019 1116
DOI: 10.1021/acschemneuro.9b00114 ACS Chem. Neurosci. 2019, 10, 1116−1116
